Latest News

July's FDA news was quiet, but an infant AD filing, JAK-refractory alopecia data, and a new device clearance hint at what's next.

Catch Up on Coverage From Day 1 of the 3rd Annual Elevate-Derm Summer Conference

Dermatology Times is looking back on the top stories in dermatology from the month of July.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of July.

Phase 1 results show Bambusa Therapeutics’ BBT001 quickly reduces atopic dermatitis and itch, sustains type 2 biomarker suppression, and may enable quarterly dosing.

As we wrap up July, explore the new sunscreen ingredient approval, debunk summer skin care myths, and learn how UV damage and therapies are shaping skin cancer prevention today.

Our July issue tackles melanoma surgery challenges, melasma in skin of color, new bemotrizinol sunscreen, atopic dermatitis breakthroughs, and billing insights from Whitney Hovenic, MD, Joseph Gatti, DMSc, Rivkah Epstein, PA-C, and more.

Catch up on all of our coverage from this year's Society for Pediatric Dermatology annual meeting.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Live from SPD 2026; learn how dermatologists can spot teen body dysmorphia, avoid reassurance traps, and use quick in-clinic tools to trigger early mental health referral.

Honored with a top pediatric dermatology award, Amy Paller, MD, MS, shares her mentorship roots, career highlights, and continued advocacy for new treatments and research.

Sarah Chamlin, MD, and Jonathan Dyer, MD, shared practical guidance on treating ulcerated infantile hemangiomas and assessing café-au-lait spots, emphasizing pain control, propranolol, follow-up, and genetics.

Sanofi will not submit the OX40-ligand antibody for regulatory review, citing efficacy and safety data insufficient to improve upon current standard-of-care treatments for moderate to severe AD.